Nivolumab in NSCLC: Indication of major added benefit for under 75-year-olds
Nivolumab is an anti-tumour drug from the group of monoclonal antibodies. It has been available since June 2015 under the trade name Opdivo for adults with advanced melanoma, and since July 2015 under the trade name Nivolumab ...
Nov 18, 2015
0
4